Piqray

Genentech

Pharma

Roche burnishes breast cancer portfolio with FDA nod for Itovebi

To be marketed under the brand name Itovebi, inavolisib is a threat to Novartis’ fellow PI3K inhibitor Piqray and AstraZeneca’s AKT inhibitor Truqap.

Angus Liu Oct 10, 2024 5:30pm

AZ's first-in-class breast cancer approval marred by restriction

Nov 17, 2023 11:02am

Novartis' new rare disease drug Vijoice meant as 'blank canvas'

Aug 10, 2022 10:29am

Piqray

Novartis gains FDA approval for Vijoice for rare condition PROS

Apr 6, 2022 9:19am

Novartis rare disease comic book cover PIK3CA mutations

Novartis' rare disease campaign draws on comic book characters

Aug 30, 2021 9:50am

Novartis social media campaign on breast cancer health inequities

Novartis' campaign tackles inequities in breast cancer health

Jun 14, 2021 8:00am